Chemical biology and pharmacology of histone lysine methylation inhibitors
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Chemical biology and pharmacology of histone lysine methylation inhibitors
Authors
Keywords
-
Journal
Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
Volume 1865, Issue 6, Pages 194840
Publisher
Elsevier BV
Online
2022-06-24
DOI
10.1016/j.bbagrm.2022.194840
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- DOT1L is a novel cancer stem cell target for triple negative breast cancer
- (2022) Hetakshi Kurani et al. CLINICAL CANCER RESEARCH
- Acquired resistance to EZH2 inhibitor GSK343 promotes the differentiation of human DLBCL cell lines towards an ABC-like phenotype
- (2022) Samuel E J Preston et al. MOLECULAR CANCER THERAPEUTICS
- Induction of senescence-associated secretory phenotype underlies the therapeutic efficacy of PRC2 inhibition in cancer
- (2022) Liping Chu et al. Cell Death & Disease
- Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
- (2022) Warren Fiskus et al. Blood Cancer Journal
- Validating Small Molecule Chemical Probes for Biological Discovery
- (2022) Victoria Vu et al. Annual Review of Biochemistry
- Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies
- (2022) Ying Huang et al. JOURNAL OF MEDICINAL CHEMISTRY
- EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis
- (2022) Jun Wang et al. NATURE CELL BIOLOGY
- Roles for the methyltransferase SETD8 in DNA damage repair
- (2022) Libo Xu et al. Clinical Epigenetics
- A Systematic Review to Define the Multi-Faceted Role of Lysine Methyltransferase SETD7 in Cancer
- (2022) Fátima Liliana Monteiro et al. Cancers
- The Role of Lysine Methyltransferase SET7/9 in Proliferation and Cell Stress Response
- (2022) Alexandra Daks et al. Life-Basel
- Pharmacokinetics and pharmacodynamic interaction of bergamottin with atorvastatin in rats
- (2022) Xinjuan Zhang et al. XENOBIOTICA
- Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease
- (2021) Kamakoti P. Bhat et al. NATURE REVIEWS DRUG DISCOVERY
- Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2
- (2021) Zhihao Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity
- (2021) Navin R. Mahadevan et al. Cancer Discovery
- The Promise and Peril of Chemical Probe Negative Controls
- (2021) Jinyoung Lee et al. ACS Chemical Biology
- The duality of PRDM proteins: epigenetic and structural perspectives
- (2021) Federico Di Tullio et al. FEBS Journal
- Loss-of-function and missense variants in NSD2 cause decreased methylation activity and are associated with a distinct developmental phenotype
- (2021) Paolo Zanoni et al. GENETICS IN MEDICINE
- Design, Synthesis, and Evaluation of WD-Repeat-Containing Protein 5 (WDR5) Degraders
- (2021) Anja Dölle et al. JOURNAL OF MEDICINAL CHEMISTRY
- Protein arginine methylation: from enigmatic functions to therapeutic targeting
- (2021) Qin Wu et al. NATURE REVIEWS DRUG DISCOVERY
- The roles of Polycomb repressive complexes in mammalian development and cancer
- (2021) Andrea Piunti et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting protein lysine methyltransferase G9A impairs self-renewal of chronic myelogenous leukemia stem cells via upregulation of SOX6
- (2021) Min Zhou et al. ONCOGENE
- DNMT1 reads heterochromatic H4K20me3 to reinforce LINE-1 DNA methylation
- (2021) Wendan Ren et al. Nature Communications
- 1525MO Phase I/II study of MAK683 in patients (pts) with advanced malignancies including epithelioid sarcoma
- (2021) R. Bahleda et al. ANNALS OF ONCOLOGY
- Combined EZH2 Inhibition and IKAROS Degradation Leads to Enhanced Antitumor Activity in Diffuse Large B-cell Lymphoma
- (2021) Kit I. Tong et al. CLINICAL CANCER RESEARCH
- FIRST‐IN‐HUMAN STUDY OF THE EZH1 AND EZH2 DUAL INHIBITOR VALEMETOSTAT TOSYLATE (DS‐3201B) IN PATIENTS WITH RELAPSED OR REFRACTORY NON‐HODGKIN LYMPHOMAS
- (2021) K Ishitsuka et al. HEMATOLOGICAL ONCOLOGY
- Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors.
- (2021) Nehal J. Lakhani et al. JOURNAL OF CLINICAL ONCOLOGY
- Design, Synthesis, and Evaluation of VHL-Based EZH2 Degraders to Enhance Therapeutic Activity against Lymphoma
- (2021) Yalin Tu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of DDO-2213 as a Potent and Orally Bioavailable Inhibitor of the WDR5–Mixed Lineage Leukemia 1 Protein–Protein Interaction for the Treatment of MLL Fusion Leukemia
- (2021) Weilin Chen et al. JOURNAL OF MEDICINAL CHEMISTRY
- The molecular principles of gene regulation by Polycomb repressive complexes
- (2021) Neil P. Blackledge et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma
- (2021) Laurie Herviou et al. Clinical Epigenetics
- The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma
- (2021) Xing Wang et al. Cancers
- Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models
- (2021) John A. Davis et al. BLOOD
- The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML
- (2021) Emily B. Heikamp et al. BLOOD
- Phase I/II Study of MAK683 in Patients with Advanced Malignancies, Including Diffuse Large B-Cell Lymphoma
- (2021) Vincent Ribrag et al. BLOOD
- Recent Progress of Small Molecule Menin–MLL Interaction Inhibitors as Therapeutic Agents for Acute Leukemia
- (2021) Hao Lei et al. JOURNAL OF MEDICINAL CHEMISTRY
- A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization
- (2021) David Dilworth et al. Nature Chemical Biology
- CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping
- (2021) Thomas Naert et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models
- (2021) Xufen Yu et al. Science Translational Medicine
- EZH2 presents a therapeutic target for neuroendocrine tumors of the small intestine
- (2021) Elham Barazeghi et al. Scientific Reports
- Structure, Activity, and Function of the Protein Lysine Methyltransferase G9a
- (2021) Coralie Poulard et al. Life-Basel
- Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors
- (2020) Hualong He et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
- (2020) George M. Burslem et al. CELL
- A LYSA Phase Ib Study of tazemetostat (EPZ-6438) plus R-CHOP in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) patients with poor prognosis features
- (2020) Clémentine Sarkozy et al. CLINICAL CANCER RESEARCH
- Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia
- (2020) Hannah J. Uckelmann et al. SCIENCE
- Inhibition of methyltransferase activity of enhancer of zeste 2 leads to enhanced lipid accumulation and altered chromatin status in zebrafish
- (2020) Marjo J. den Broeder et al. Epigenetics & Chromatin
- Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target
- (2020) Krzysztof Brzezinka et al. Cancers
- Targeted Protein Degradation: An Emerging Therapeutic Strategy in Cancer.
- (2020) Samir H. Barghout Anti-Cancer Agents in Medicinal Chemistry
- Epigenetic Therapy for Epithelioid Sarcoma
- (2020) Scott B. Rothbart et al. CELL
- Tazemetostat: First Approval
- (2020) Sheridan M. Hoy DRUGS
- Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin–MLL Interaction with Strong In Vivo Antitumor Activity
- (2020) Shilin Xu et al. JOURNAL OF MEDICINAL CHEMISTRY
- The NSD2 p.E1099K Mutation is Enriched at Relapse and Confers Drug Resistance in a Cell Context Dependent Manner in Pediatric Acute Lymphoblastic Leukemia
- (2020) Joanna Pierro et al. MOLECULAR CANCER RESEARCH
- Evaluation of VTP‐50469, a menin‐MLL1 inhibitor, against Ewing sarcoma xenograft models by the pediatric preclinical testing consortium
- (2020) Raushan T. Kurmasheva et al. PEDIATRIC BLOOD & CANCER
- Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality
- (2020) Milka Kostic et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Increased Efficacy of Histone Methyltransferase G9a Inhibitors Against MYCN-Amplified Neuroblastoma
- (2020) Jacob Bellamy et al. Frontiers in Oncology
- Synergistic Targeting of FLT3 Mutations in AML via Combined Menin-MLL and FLT3 Inhibition
- (2020) Margarita M. Dzama et al. BLOOD
- NPM1-mutated acute myeloid leukemia: from bench to bedside
- (2020) Brunangelo Falini et al. BLOOD
- EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development
- (2020) Rohan Kalyan Rej et al. JOURNAL OF MEDICINAL CHEMISTRY
- Epigenetic Therapies for Cancer
- (2020) Susan E. Bates NEW ENGLAND JOURNAL OF MEDICINE
- Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of MLL-Rearrangements: A Novel Therapeutic Strategy for Pediatric AML
- (2020) Annalisa Lonetti et al. Cancers
- NSD3-induced methylation of H3K36 activates NOTCH signaling to drive breast tumor initiation and metastatic progression
- (2020) Ga-Young Jeong et al. CANCER RESEARCH
- Clinical and prognostic significance of t(4;14) translocation in multiple myeloma in the era of novel agents
- (2020) Shuku Sato et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich’s ataxia patient cells
- (2020) Gabriela Vilema-Enríquez et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Covalent inhibition of NSD1 histone methyltransferase
- (2020) Huang Huang et al. Nature Chemical Biology
- In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models—A report from the Pediatric Preclinical Testing Consortium
- (2020) Raushan T. Kurmasheva et al. PEDIATRIC BLOOD & CANCER
- Histone methyltransferase DOT1L coordinates AR and MYC stability in prostate cancer
- (2020) R. Vatapalli et al. Nature Communications
- Molecular basis of nucleosomal H3K36 methylation by NSD methyltransferases
- (2020) Wanqiu Li et al. NATURE
- EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma
- (2020) Ananya Pal et al. eLife
- Targeting histone K4 trimethylation for treatment of cognitive and synaptic deficits in mouse models of Alzheimer’s disease
- (2020) Qing Cao et al. Science Advances
- Immunologic correlates of the abscopal effect in a SMARCB1/INI1-negative Poorly Differentiated Chordoma after EZH2 inhibition and radiotherapy
- (2019) Mrinal M. Gounder et al. CLINICAL CANCER RESEARCH
- Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells
- (2019) Evelyne Lima-Fernandes et al. Nature Communications
- Roles of SETD2 in Leukemia—Transcription, DNA-Damage, and Beyond
- (2019) Anna Skucha et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells
- (2019) Shuo Huang et al. CANCER RESEARCH
- Inhibition of G9a by a small molecule inhibitor, UNC0642, induces apoptosis of human bladder cancer cells
- (2019) Yue-peng Cao et al. ACTA PHARMACOLOGICA SINICA
- EZH2 is overexpressed in BRCA1-like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy
- (2019) Julian Puppe et al. CLINICAL CANCER RESEARCH
- Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas
- (2019) Jennifer K Lue et al. CLINICAL CANCER RESEARCH
- Emerging Roles for Polycomb-Group Proteins in Stem Cells and Cancer
- (2019) Ho Lam Chan et al. TRENDS IN BIOCHEMICAL SCIENCES
- Targeting protein methylation: from chemical tools to precision medicines
- (2019) David Dilworth et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein–Protein Interaction
- (2019) Angelo Aguilar et al. JOURNAL OF MEDICINAL CHEMISTRY
- Fragment-based discovery of a chemical probe for the PWWP1 domain of NSD3
- (2019) Jark Böttcher et al. Nature Chemical Biology
- Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
- (2019) Cristina Segovia et al. NATURE MEDICINE
- The regulation, functions and clinical relevance of arginine methylation
- (2019) Ernesto Guccione et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Roles and regulation of histone methylation in animal development
- (2019) Ashwini Jambhekar et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The roles of DNA, RNA and histone methylation in ageing and cancer
- (2019) Ewa M. Michalak et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- DOT1L inhibition reveals a distinct subset of enhancers dependent on H3K79 methylation
- (2019) Laura Godfrey et al. Nature Communications
- Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft
- (2019) Silvia Stacchiotti et al. Cancers
- EED inhibition suppresses cancers by modulating the immune response
- (2019) Hongping Dong et al. CANCER RESEARCH
- Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors
- (2019) Timothy A. Yap et al. CLINICAL CANCER RESEARCH
- Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers
- (2019) Liye Zhou et al. CLINICAL CANCER RESEARCH
- Inhibition of DOT1L and PRMT5 promote synergistic anti-tumor activity in a human MLL leukemia model induced by CRISPR/Cas9
- (2019) Kathy-Ann Secker et al. ONCOGENE
- A Phase Ib/II Study of the Histone Methyltransferase Inhibitor Pinometostat in Combination with Azacitidine in Patients with 11q23-Rearranged Acute Myeloid Leukemia
- (2019) Kamal Menghrajani et al. BLOOD
- Engaging chromatin: PRC2 structure meets function
- (2019) Paul Chammas et al. BRITISH JOURNAL OF CANCER
- GSK343 induces programmed cell death through the inhibition of EZH2 and FBP1 in osteosarcoma cells
- (2019) Xifeng Xiong et al. CANCER BIOLOGY & THERAPY
- ATRX In-Frame Fusion Neuroblastoma Is Sensitive to EZH2 Inhibition via Modulation of Neuronal Gene Signatures
- (2019) Zulekha A. Qadeer et al. CANCER CELL
- Targeted protein degradation: expanding the toolbox
- (2019) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- Histone lysine methyltransferases in biology and disease
- (2019) Dylan Husmann et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- EZH2 targeting reduces medulloblastoma growth through epigenetic reactivation of the BAI1/p53 tumor suppressor pathway
- (2019) Hanwen Zhang et al. ONCOGENE
- Genotoxic stress-triggered β-catenin/JDP2/PRMT5 complex facilitates reestablishing glutathione homeostasis
- (2019) Lixue Cao et al. Nature Communications
- Targeting Excessive EZH1 and EZH2 Activities for Abnormal Histone Methylation and Transcription Network in Malignant Lymphomas
- (2019) Makoto Yamagishi et al. Cell Reports
- A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia
- (2019) Andrei V. Krivtsov et al. CANCER CELL
- DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment
- (2019) Federica Sarno et al. Epigenetics
- Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia
- (2019) Szymon Klossowski et al. JOURNAL OF CLINICAL INVESTIGATION
- Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse
- (2019) Guillermo Urrutia et al. MOLECULAR CANCER RESEARCH
- Discovery of a first-in-class EZH2 selective degrader
- (2019) Anqi Ma et al. Nature Chemical Biology
- Discovery of a chemical probe for PRDM9
- (2019) Abdellah Allali-Hassani et al. Nature Communications
- Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer
- (2019) Liqun Yang et al. Clinical Epigenetics
- Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction
- (2018) Shilin Xu et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- 42OA phase 1 study of CPI-1205, a small molecule inhibitor of EZH2, preliminary safety in patients with B-cell lymphomas
- (2018) W Harb et al. ANNALS OF ONCOLOGY
- The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia
- (2018) Eytan M. Stein et al. BLOOD
- WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage
- (2018) Beth K. Neilsen et al. BMC CANCER
- EZH2 Inhibition Ameliorates Transverse Aortic Constriction-Induced Pulmonary Arterial Hypertension in Mice
- (2018) Zhan-Li Shi et al. Canadian Respiratory Journal
- Chemical and Biochemical Perspectives of Protein Lysine Methylation
- (2018) Minkui Luo CHEMICAL REVIEWS
- Identification of Rpl29 as a major substrate of the lysine methyltransferase Set7/9
- (2018) Tewfik Hamidi et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Complexity of Blocking Bivalent Protein–Protein Interactions: Development of a Highly Potent Inhibitor of the Menin–Mixed-Lineage Leukemia Interaction
- (2018) Dmitry Borkin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Unique Structural Platforms of Suz12 Dictate Distinct Classes of PRC2 for Chromatin Binding
- (2018) Siming Chen et al. MOLECULAR CELL
- In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis
- (2018) Qibiao Wu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PRDM9 and Its Role in Genetic Recombination
- (2018) Kenneth Paigen et al. TRENDS IN GENETICS
- Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin’s Lymphoma
- (2018) Biao Lu et al. ACS Medicinal Chemistry Letters
- Targeting EZH2 reactivates a breast cancer subtype-specific anti-metastatic transcriptional program
- (2018) Alison Hirukawa et al. Nature Communications
- Moonlighting with WDR5: A Cellular Multitasker
- (2018) Alissa Guarnaccia et al. Journal of Clinical Medicine
- Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
- (2018) Sangeeta Goswami et al. JOURNAL OF CLINICAL INVESTIGATION
- Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds
- (2018) Rossella Fioravanti et al. CHEMICAL RECORD
- Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities
- (2018) Michela Serresi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains
- (2018) Jean-Philippe Lambert et al. MOLECULAR CELL
- FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer
- (2018) Yun-Cheol Chae et al. NUCLEIC ACIDS RESEARCH
- The Histone H3 Lysine 4 Presenter WDR5 as an Oncogenic Protein and Novel Epigenetic Target in Cancer
- (2018) Kebin Lu et al. Frontiers in Oncology
- Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L
- (2017) Nigel J. Waters EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS
- EZH2 inhibitors: a patent review (2014-2016)
- (2017) Giulia Stazi et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase
- (2017) Yan Xiong et al. JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of Orally Bioavailable Enhancer of Zeste Homolog 2 (EZH2) Inhibitors Using Ligand and Property-Based Design Strategies: Identification of Development Candidate (R)-5,8-Dichloro-7-(methoxy(oxetan-3-yl)methyl)-2-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3,4-dihydroisoquinolin-1(2H)-one (PF-06821497)
- (2017) Pei-Pei Kung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)–Mixed Lineage Leukemia (MLL) Protein–Protein Interaction
- (2017) Hacer Karatas et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia
- (2017) S Fujita et al. LEUKEMIA
- The MLL recombinome of acute leukemias in 2017
- (2017) C Meyer et al. LEUKEMIA
- Transcription control by the ENL YEATS domain in acute leukaemia
- (2017) Michael A. Erb et al. NATURE
- An allosteric PRC2 inhibitor targeting the H3K27me3 binding pocket of EED
- (2017) Wei Qi et al. Nature Chemical Biology
- The EED protein–protein interaction inhibitor A-395 inactivates the PRC2 complex
- (2017) Yupeng He et al. Nature Chemical Biology
- The SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity
- (2017) Kenneth D Bromberg et al. Nature Chemical Biology
- WD40 repeat domain proteins: a novel target class?
- (2017) Matthieu Schapira et al. NATURE REVIEWS DRUG DISCOVERY
- PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors
- (2017) Thomas Januario et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Waste disposal—An attractive strategy for cancer therapy
- (2017) Jemilat Salami et al. SCIENCE
- The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells
- (2017) Tianfu Yu et al. Oncotarget
- UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition
- (2017) Teresa Ezponda et al. Cell Reports
- The Role of Nuclear Receptor–Binding SET Domain Family Histone Lysine Methyltransferases in Cancer
- (2017) Richard L. Bennett et al. Cold Spring Harbor Perspectives in Medicine
- Protein lysine methylation by seven- -strand methyltransferases
- (2016) P. O. Falnes et al. BIOCHEMICAL JOURNAL
- Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)–WDR5 interaction
- (2016) Dong-Dong Li et al. BIOORGANIC & MEDICINAL CHEMISTRY
- DOT1L as a therapeutic target for the treatment of DNMT3A -mutant acute myeloid leukemia
- (2016) Rachel E. Rau et al. BLOOD
- Progress in the Development of Lysine Methyltransferase SETD8 Inhibitors
- (2016) Ciro Milite et al. ChemMedChem
- The role of DOT1L in the maintenance of leukemia gene expression
- (2016) Xi Wang et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- A PWWP Domain of Histone-LysineN-Methyltransferase NSD2 Binds to Dimethylated Lys-36 of Histone H3 and Regulates NSD2 Function at Chromatin
- (2016) Saumya M. Sankaran et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Property Focused Structure-Based Optimization of Small Molecule Inhibitors of the Protein–Protein Interaction between Menin and Mixed Lineage Leukemia (MLL)
- (2016) Dmitry Borkin et al. JOURNAL OF MEDICINAL CHEMISTRY
- Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas
- (2016) Rishi G. Vaswani et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure–Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors
- (2016) Xiaobao Yang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1)
- (2016) Matthäus Getlik et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors
- (2016) Pei-Pei Kung et al. JOURNAL OF MEDICINAL CHEMISTRY
- Structure-Based Design of a Covalent Inhibitor of the SET Domain-Containing Protein 8 (SETD8) Lysine Methyltransferase
- (2016) Kyle V. Butler et al. JOURNAL OF MEDICINAL CHEMISTRY
- NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis
- (2016) S Struski et al. LEUKEMIA
- Exploring genomic alteration in pediatric cancer using ProteinPaint
- (2016) Xin Zhou et al. NATURE GENETICS
- Targeting the histone methyltransferase G9a activates imprinted genes and improves survival of a mouse model of Prader–Willi syndrome
- (2016) Yuna Kim et al. NATURE MEDICINE
- An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation
- (2016) George P Souroullas et al. NATURE MEDICINE
- Targeting EZH2 in cancer
- (2016) Kimberly H Kim et al. NATURE MEDICINE
- The molecular hallmarks of epigenetic control
- (2016) C. David Allis et al. NATURE REVIEWS GENETICS
- Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2
- (2016) Neil Justin et al. Nature Communications
- Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance
- (2016) Alexei Brooun et al. Nature Communications
- Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2
- (2016) H. Xie et al. Cancer Discovery
- Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
- (2016) H. Zhang et al. Cancer Discovery
- Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer
- (2016) Xuejiao Song et al. Scientific Reports
- Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial Sarcoma in vitro
- (2016) Jacson K. Shen et al. Scientific Reports
- Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/ -globin looping
- (2015) I. Krivega et al. BLOOD
- Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner
- (2015) M. Mochizuki-Kashio et al. BLOOD
- Pharmacologic Inhibition of the Menin-MLL Interaction Blocks Progression of MLL Leukemia In Vivo
- (2015) Dmitry Borkin et al. CANCER CELL
- Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia
- (2015) Florian Grebien et al. Nature Chemical Biology
- The promise and peril of chemical probes
- (2015) Cheryl H Arrowsmith et al. Nature Chemical Biology
- DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia
- (2015) Chun-Wei Chen et al. NATURE MEDICINE
- SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2
- (2015) Kimberly H Kim et al. NATURE MEDICINE
- Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
- (2015) Benjamin G Bitler et al. NATURE MEDICINE
- Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
- (2015) V Gibaja et al. ONCOGENE
- Targeting histone lysine methylation in cancer
- (2015) John McGrath et al. PHARMACOLOGY & THERAPEUTICS
- Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2
- (2015) L. Jiao et al. SCIENCE
- EPZ011989, A Potent, Orally-Available EZH2 Inhibitor with Robust in Vivo Activity
- (2015) John E. Campbell et al. ACS Medicinal Chemistry Letters
- The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors
- (2015) Daniel Zingg et al. Nature Communications
- Abstract 1697: CPI-169, a novel and potent EZH2 inhibitor, synergizes with CHOPin vivoand achieves complete regression in lymphoma xenograft models
- (2015) Vidya Balasubramanian et al. CANCER RESEARCH
- The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia
- (2015) William N. Pappano et al. PLoS One
- Genetic alterations of histone lysine methyltransferases and their significance in breast cancer
- (2015) Lanxin Liu et al. Oncotarget
- Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia
- (2014) B. Xu et al. BLOOD
- AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes
- (2014) Aniruddha J. Deshpande et al. CANCER CELL
- The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle
- (2014) Wootae Kim et al. CELL CYCLE
- EZH2 Inhibitor Efficacy in Non-Hodgkin’s Lymphoma Does Not Require Suppression of H3K27 Monomethylation
- (2014) William D. Bradley et al. CHEMISTRY & BIOLOGY
- Challenges and opportunities in targeting the menin–MLL interaction
- (2014) Tomasz Cierpicki et al. Future Medicinal Chemistry
- High-Affinity Small-Molecule Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction Closely Mimic a Natural Protein–Protein Interaction
- (2014) Shihan He et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8
- (2014) Anqi Ma et al. JOURNAL OF MEDICINAL CHEMISTRY
- The emerging roles of DOT1L in leukemia and normal development
- (2014) C M McLean et al. LEUKEMIA
- Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitro
- (2014) S M Sarkaria et al. LEUKEMIA
- Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia
- (2014) Fang Cao et al. MOLECULAR CELL
- Structure of the DDB1–CRBN E3 ubiquitin ligase in complex with thalidomide
- (2014) Eric S. Fischer et al. NATURE
- SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer
- (2014) Pawel K. Mazur et al. NATURE
- (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells
- (2014) D. Barsyte-Lovejoy et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structure and function of the nucleosome-binding PWWP domain
- (2014) Su Qin et al. TRENDS IN BIOCHEMICAL SCIENCES
- Discovery and Development of Potent and Selective Inhibitors of Histone Methyltransferase G9a
- (2014) Ramzi F. Sweis et al. ACS Medicinal Chemistry Letters
- Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2
- (2014) Christopher G. Nasveschuk et al. ACS Medicinal Chemistry Letters
- The central role of EED in the orchestration of polycomb group complexes
- (2014) Qi Cao et al. Nature Communications
- Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation
- (2014) Goro Sashida et al. Nature Communications
- NSD3-NUT Fusion Oncoprotein in NUT Midline Carcinoma: Implications for a Novel Oncogenic Mechanism
- (2014) C. A. French et al. Cancer Discovery
- Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation
- (2014) Relja Popovic et al. PLoS Genetics
- An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1
- (2013) Kyle D. Konze et al. ACS Chemical Biology
- BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production
- (2013) Yunha Kim et al. Autophagy
- Bromo-deaza-SAH: A potent and selective DOT1L inhibitor
- (2013) Wenyu Yu et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Potent inhibition of DOT1L as treatment of MLL-fusion leukemia
- (2013) S. R. Daigle et al. BLOOD
- EZH2 overexpression in natural killer/T-cell lymphoma confers growth advantage independently of histone methyltransferase activity
- (2013) J. Yan et al. BLOOD
- EZH2 mutations are frequent and represent an early event in follicular lymphoma
- (2013) C. Bodor et al. BLOOD
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma
- (2013) Z. Huang et al. CANCER RESEARCH
- The Histone H3 Methyltransferase G9A Epigenetically Activates the Serine-Glycine Synthesis Pathway to Sustain Cancer Cell Survival and Proliferation
- (2013) Jane Ding et al. Cell Metabolism
- Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth
- (2013) Shivani Garapaty-Rao et al. CHEMISTRY & BIOLOGY
- Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis
- (2013) Marieta Caganova et al. JOURNAL OF CLINICAL INVESTIGATION
- Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP
- (2013) Feng Liu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies
- (2013) J A Oyer et al. LEUKEMIA
- Target validation using chemical probes
- (2013) Mark E Bunnage et al. Nature Chemical Biology
- Histone H4 Lysine 20 methylation: key player in epigenetic regulation of genomic integrity
- (2013) S. Jorgensen et al. NUCLEIC ACIDS RESEARCH
- Structure of the Catalytic Domain of EZH2 Reveals Conformational Plasticity in Cofactor and Substrate Binding Sites and Explains Oncogenic Mutations
- (2013) Hong Wu et al. PLoS One
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
- (2013) S. Bea et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Menin: a scaffold protein that controls gene expression and cell signaling
- (2013) Smita Matkar et al. TRENDS IN BIOCHEMICAL SCIENCES
- Protein methylation at the surface and buried deep: thinking outside the histone box
- (2013) Steven G. Clarke TRENDS IN BIOCHEMICAL SCIENCES
- Gossypol and an HMT G9a inhibitor act in synergy to induce cell death in pancreatic cancer cells
- (2013) Y Yuan et al. Cell Death & Disease
- A Small-Molecule Probe of the Histone Methyltransferase G9a Induces Cellular Senescence in Pancreatic Adenocarcinoma
- (2012) Yuan Yuan et al. ACS Chemical Biology
- Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5
- (2012) Guillermo Senisterra et al. BIOCHEMICAL JOURNAL
- Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia
- (2012) A. Shi et al. BLOOD
- A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia
- (2012) C. Simon et al. GENES & DEVELOPMENT
- Abrogation of MLL–AF10 and CALM–AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l
- (2012) L Chen et al. LEUKEMIA
- Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact
- (2012) Joshua C. Black et al. MOLECULAR CELL
- Characterization of the EZH2-MMSET Histone Methyltransferase Regulatory Axis in Cancer
- (2012) Irfan A. Asangani et al. MOLECULAR CELL
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- New lysine methyltransferase drug targets in cancer
- (2012) Tobias Wagner et al. NATURE BIOTECHNOLOGY
- Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia
- (2012) Jolanta Grembecka et al. Nature Chemical Biology
- A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
- (2012) Sarah K Knutson et al. Nature Chemical Biology
- Understanding the language of Lys36 methylation at histone H3
- (2012) Eric J. Wagner et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Nahuoic Acid A Produced by a Streptomyces sp. Isolated From a Marine Sediment Is a Selective SAM-Competitive Inhibitor of the Histone Methyltransferase SETD8
- (2012) David E. Williams et al. ORGANIC LETTERS
- Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
- (2012) M. T. McCabe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
- (2012) W. Qi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent
- (2012) K. Xu et al. SCIENCE
- Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2
- (2012) Sharad K. Verma et al. ACS Medicinal Chemistry Letters
- Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors
- (2012) Wenyu Yu et al. Nature Communications
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Mutations in EZH2 Cause Weaver Syndrome
- (2011) William T. Gibson et al. AMERICAN JOURNAL OF HUMAN GENETICS
- DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis
- (2011) A. T. Nguyen et al. BLOOD
- NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern
- (2011) I. H. I. M. Hollink et al. BLOOD
- Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor
- (2011) Scott R. Daigle et al. CANCER CELL
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
- (2011) Kathrin M. Bernt et al. CANCER CELL
- EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling
- (2011) Chun-Ju Chang et al. CANCER CELL
- Chemogenetic Analysis of Human Protein Methyltransferases
- (2011) Victoria M. Richon et al. Chemical Biology & Drug Design
- H3K9 methyltransferase G9a and the related molecule GLP
- (2011) Y. Shinkai et al. GENES & DEVELOPMENT
- EZH2 Y641 mutations in follicular lymphoma
- (2011) C Bödör et al. LEUKEMIA
- p53-Dependent Transcription and Tumor Suppression Are Not Affected in Set7/9-Deficient Mice
- (2011) Bernhard Lehnertz et al. MOLECULAR CELL
- Histone Methylation by PRC2 Is Inhibited by Active Chromatin Marks
- (2011) Frank W. Schmitges et al. MOLECULAR CELL
- The Polycomb complex PRC2 and its mark in life
- (2011) Raphaël Margueron et al. NATURE
- A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells
- (2011) Masoud Vedadi et al. Nature Chemical Biology
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Epigenetic regulation of development by histone lysine methylation
- (2010) S Dambacher et al. HEREDITY
- Uncovering the Human Methyltransferasome
- (2010) Tanya C. Petrossian et al. MOLECULAR & CELLULAR PROTEOMICS
- Regulation of the Histone H4 Monomethylase PR-Set7 by CRL4Cdt2-Mediated PCNA-Dependent Degradation during DNA Damage
- (2010) Hisanobu Oda et al. MOLECULAR CELL
- Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes
- (2010) Gorica Nikoloski et al. NATURE GENETICS
- Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
- (2010) Ryan D Morin et al. NATURE GENETICS
- Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
- (2010) Thomas Ernst et al. NATURE GENETICS
- Post-translational modifications in signal integration
- (2010) Yonathan Lissanu Deribe et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas
- (2010) C. J. Sneeringer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Identification of a Primary Target of Thalidomide Teratogenicity
- (2010) T. Ito et al. SCIENCE
- NUP98–NSD3 fusion gene in radiation-associated myelodysplastic syndrome with t(8;11)(p11;p15) and expression pattern of NSD family genes
- (2009) Takeshi Taketani et al. CANCER GENETICS AND CYTOGENETICS
- DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
- (2009) T. B. Miranda et al. MOLECULAR CANCER THERAPEUTICS
- A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf–Hirschhorn syndrome
- (2009) Keisuke Nimura et al. NATURE
- Role of the polycomb protein EED in the propagation of repressive histone marks
- (2009) Raphael Margueron et al. NATURE
- Regulation of NF- B by NSD1/FBXL11-dependent reversible lysine methylation of p65
- (2009) T. Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Epigenetic-Mediated Dysfunction of the Bone Morphogenetic Protein Pathway Inhibits Differentiation of Glioblastoma-Initiating Cells
- (2008) Jeongwu Lee et al. CANCER CELL
- A chromatin-wide transition to H4K20 monomethylation impairs genome integrity and programmed DNA rearrangements in the mouse
- (2008) G. Schotta et al. GENES & DEVELOPMENT
- Role of the Histone H3 Lysine 4 Methyltransferase, SET7/9, in the Regulation of NF-κB-dependent Inflammatory Genes
- (2008) Yan Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms
- (2008) Raphael Margueron et al. MOLECULAR CELL
- Nonprocessive methylation by Dot1 leads to functional redundancy of histone H3K79 methylation states
- (2008) Floor Frederiks et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started